Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of LAIS Grass sublingual immunotherapy for grass pollen-induced allergic rhinoconjunctivitis
2012-004916-79Phase 3Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Nov 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Lais Graminacee in allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR), sponsored by Lofarma S.p.A. Primary endpoint: Total Combined Score during peak grass pollen season. Started Nov 2012; status: completed.
02
Drugs
Lais Graminacee
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2012-004916-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004916-79.